The Application segment delineates the end‑use environments where glucose electrochemical biosensors generate revenue. Diabetes management dominates the market, accounting for roughly 55% of total sales, driven by the high prevalence of diabetes and the need for continuous glucose monitoring (CGM) systems. Clinical diagnostics contributes about 20%, reflecting hospital and laboratory adoption for blood glucose testing, where accuracy and integration with automated analyzers are critical. Research & development represents 15% of the market, encompassing academic and pharmaceutical labs that employ biosensors for metabolic studies, drug screening, and assay validation. Finally, point‑of‑care testing holds a 10% share, catering to decentralized settings such as pharmacies and home health, where rapid, user‑friendly devices are essential. Collectively, these application categories form the basis of the Glucose Electrochemical Biosensors segmentation, each influencing the overall market size through distinct demand drivers and pricing structures.